Edrecolomab ELISA Kit

Catalog No.

KDD17401

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant Human CD326 has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Edrecolomab present is bound by the immobilized protein. After washing away any unbound substances, a HRP conjugated probe is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Edrecolomab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Edrecolomab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

15.63 - 1,000 ng/mL

Sensitivity

3.11 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	433.4	107.5	22.2	485.0	113.4	25.2
Standard deviation	36.4	7.6	1.2	29.7	4.0	3.5
CV (%)	8.4	7.0	5.2	6.1	3.5	14.1

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

17-1A, CAS: 156586-89-9

Background

Edrecolomab, also known as MAb17-1A, is a mouse-derived IgG2a monoclonal antibody targeted at the cell-surface glycoprotein EpCAM (17-1A). This drug was developed by Centocor in an attempt to prevent colorectal cancer and adenocarcinoma. Edrecolomab has been investigated in the clinical trials for the treatment of colon cancer. Edrecolomab was licensed as an adjuvant therapy for postoperative colorectal cancer by German authorities with the trade name Panorex in 1995. However, in 2004, researchers applied edrecolomab to the study of postoperative adjuvant therapy in patients with colorectal cancer. The results showed that edrecolomab adjuvant therapy can help Dukes'CCRC patients to restore the lack of immune response in the body, but the randomized trials of clinical efficacy were unsatisfactory. Then in 2005, Edrecolomab was studied in a phase 3 randomized trial of postoperative adjuvant therapy for colorectal cancer. However, the results showed that Edrecolomab did not improve overall survival or disease-free survival in patients with stage II colon cancer treated with postoperative adjuvant therapy. Subsequently, Edrecolomab in combination with fluorouracil (FU) was used to treat colorectal cancer in the III stage. However, the results showed that the addition of ED in the basic treatment of fluorouracil had no significant effect on OS. Edrecolomab also did not prolong patient survival in subsequent randomized trials. Although Edrecolomab has not shown very good results in previous studies of colorectal cancer, it is still a promising monoclonal antibody for the treatment of adenocarcinomas expressing EpCAM.

Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials., PMID:29966444

Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition., PMID:29667344

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs., PMID:29329202

Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update., PMID:29295696

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)., PMID:27432924

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581., PMID:23530100

Marketed therapeutic antibodies compendium., PMID:22531442

Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803., PMID:21747089

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581., PMID:21747085

[Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review]., PMID:21129296

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies., PMID:21044305

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment., PMID:21042730

Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside., PMID:20426706

EpCAM as a target in cancer therapy., PMID:20385979

Letter to the editor: efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309-1., PMID:20079406

EpCAM: a potential antimetastatic target for gastric cancer., PMID:19941073

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer., PMID:19273708

When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab., PMID:19273695

Yeast cell surface display system for determination of humoral response to active immunization with a monoclonal antibody against EpCAM., PMID:18321588

Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody 17-1A and interleukin-2., PMID:17562330

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges., PMID:17325709

Expression of EpCAM in uveal melanoma., PMID:17125516

Recent developments in colorectal cancer treatment by monoclonal antibodies., PMID:17049015

Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer., PMID:16955700

Monoclonal and bispecific antibodies as novel therapeutics., PMID:16648969

Expression of epithelial-cell adhesion molecule (Ep-CAM) in small cell lung cancer as defined by monoclonal antibodies 17-1A and BerEP4., PMID:16227163

Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study., PMID:15933423

Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy., PMID:15933417

[Anti-cancer monoclonal antibody]., PMID:15861718

Adjuvant therapy of colon cancer., PMID:15726511

The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study., PMID:15713997

[Adjuvant therapy for colon cancer]., PMID:15497107

Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma., PMID:15289873

Monoclonal antibodies in the treatment of colorectal cancer., PMID:15177487

Monoclonal antibodies as therapeutic agents for cancer., PMID:15120666

Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model., PMID:14593230

EpCAM: A new therapeutic target for an old cancer antigen., PMID:14508099

Monoclonal antibodies in the treatment of cancer, Part 2., PMID:12966906

Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study., PMID:12962368

Monoclonal antibodies in the treatment of cancer, Part 1., PMID:12951753

A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma., PMID:12743982

Adjuvant therapy for colon cancer in the new millenium., PMID:12705552

Edrecolomab in the adjuvant treatment of colorectal carcinoma., PMID:12517502

Edrecolomab in the adjuvant treatment of colorectal carcinoma., PMID:12517501

Highlights from: 38th annual meeting of the American Society of Clinical Oncology., PMID:12453319

Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer., PMID:12445374

25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000., PMID:12445373

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study., PMID:12241873

Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells., PMID:12176782

In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment., PMID:12115595

Document Download

Edrecolomab ELISA Kit.pdf